Due to the site upgrade, your MY ACCOUNT logins will need to be updated. Please access Forgot Your Password to make this change. If you do not have an account, click here.

Lycopene stops the progression of BPH

Jan 09, 2008



Benign prostatic hypertrophy is estimated to affect half of men in their 50s, increasing in prevalence to up to 90 percent of men age 80 and older. In this newly published study researchers of the University of Hohenheim in Stuttgart enrolled 40 men with biopsy-confirmed BPH (Benign Prostatic Hypertrophy) and a serum prostate specific antigen (PSA) concentration of greater than 4.0 micrograms per liter. The men were randomized to receive 15 milligrams of lycopene per day or inactive placebo for six months. Prostate specific antigen was measured in blood samples drawn during screening, and after one, three, and six months. Prostate volume was determined via digital rectal examination and prostate weight by trans-rectal ultrasonography.
Supplementation with the carotenoid lycopene slowed the growth of the prostate in the men. After six months, men who received lycopene experienced a decrease in PSA levels, while those who received the placebo experienced no change. Prostate enlargement progressed in the placebo group but prostate size remained the same in those that received lycopene. Although both groups reported improved BPH symptoms following the trials, a greater effect was report by men who received lycopene. The study is published in the January, 2007 issue of the Journal of Nutrition.


Yale University; Cocoa clearly improves blood flow hemodynamics and function of the arteries

In a six-week trial, healthy adults were given 8 ounces of cocoa, 8 ounces of cocoa with sugar, or placebo each day. The scientists from Yale University’s Yale Prevention Center used high-frequency ultrasound after each serving to check blood flow progress. The results were clear; improved blood flow resulted from both cocoas but was better in the sugar-free cocoa. This could improve or help prevent high blood pressure and cardiovascular disease. The paper was presented recently at the annual American College of Cardiology scientific meeting in New Orleans.